RB1 and lung cancer: Unlike AURKA inhibitors, these mitotic inhibitors did not show significant synthetic lethal effect in RB1-deficient lung cancer cells, suggesting that the synthetic lethality by AURKA inhibitors was not due to the general mitotic kinase inhibitory effect (Supplementary Fig. 3a–c).